CytoMed Therapeutics (GDTC) Net Income towards Common Stockholders (2022 - 2025)

CytoMed Therapeutics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at $7.1 million in Q2 2025.

• Quarterly Net Income towards Common Stockholders fell 29.67% year-over-year to $7.1 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $26.3 million (down 39.66% YoY) and the FY2025 annual result came in at -$3.0 million, down 133.98% from the prior year.
• Net Income towards Common Stockholders eased to $7.1 million in Q2 2025 per GDTC's latest filing, from $9.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $13.2 million in Q2 2023 and troughed at $104.0 in Q2 2022.
• A 4-year average of $7.3 million and a median of $9.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 12663048.08% in 2023, then slipped 29.67% in 2025.
• Over 4 years, Net Income towards Common Stockholders stood at $586980.0 in 2022, then soared by 1815.76% to $11.2 million in 2023, then retreated by 20.27% to $9.0 million in 2024, then retreated by 20.29% to $7.1 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $7.1 million, $9.0 million, and $10.2 million for Q2 2025, Q4 2024, and Q2 2024 respectively.